- Baudax Bio has been a miserable investment so far as the share price remains under $1.00 per share and the market cap continues to deteriorate.
- The company recently reported abysmal Q2 earnings with a big miss on EPS and revenue. However, the company did reveal some encouraging commercial trends that are not evident in financials.
- I point out a few bullish highlights that could lead to a turnaround once the pandemic is under control. However, investors need to accept the possibility these COVID-19 headwinds are likely to endure.
- I reveal my plan for managing my upsized BXRX position and how I intend to generate some profit along the way.
For further details see:
Baudax Bio: Looking For A Turnaround In Strong COVID-19 Headwinds